Search Within

Poulikos I Poulikakos

Formats
  1. Meeting Abstract (14)
  2. Journal Article (9)
Groups
  1. Department of Medicine (22)
  2. GSK Faculty (22)
  3. Solid Tumor Oncology Division (22)
  4. Breast Medicine Service (21)
  5. Molecular Pharmacology and Chemistry Program Faculty (21)
  6. Sloan Kettering Institute Faculty (21)

More Groups

People
  1. Neal Rosen (21)
  2. David Solit (10)
  3. Eric Joseph (10)
  4. Christine Pratilas (8)
  5. Madhavi Tadi (8)
  6. Sarat Chandarlapaty (7)

More People

Years
  1. 2014 (1)
  2. 2013 (3)
  3. 2012 (6)
  4. 2011 (6)
  5. 2010 (3)
  6. 2009 (1)

More Years

Publications
  1. Cancer Research (13)
  2. Cancer Cell (2)
  3. Nature (2)
  4. Cancer Discovery (1)
  5. European Journal of Cancer (1)
  6. Molecular Cancer Research (1)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. Nature Publishing Group (3)
  3. Cell Press (2)
  4. American Association for the Advancement of Science (1)
  5. Elsevier Inc. (1)
  6. National Academy of Sciences (1)

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032
    Meeting Abstract

    Poulikakos, P. I.; Persaud, Y.; Gabay, M. T.; Janakiraman, M.; Joseph, E. W.; Pratilas, C. A.; Chapman, P. B.; Rosen, N.; Solit, D. B.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • CH5126766 is a novel allosteric inhibitor of MEK that prevents its phosphorylation by RAF
    Meeting Abstract

    Ishii, N.; Harada, N.; Sakamoto, H.; Matsuda, Y.; Tomii, Y.; Tachibana-Kondo, Y.; Miura, T.; Ohara, K.; Iikura, H.; Aoki, T.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    Journal Article

    Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; more...
    Nature (2011)

    Fulltext@MSK | Save
  • mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    Journal Article

    Rodrik-Outmezguine, V. S.; Chandarlapaty, S.; Pagano, N. C.; Poulikakos, P. I.; Scaltriti, M.; Moskatel, E.; Baselga, J.; Guichard, S.; Rosen, N.
    Cancer Discovery (2011)

    Fulltext@MSK | Save
  • Resistance to MEK inhibitors: Should we co-target upstream?
    Journal Article

    Poulikakos, P. I.; Solit, D. B.
    Science Signaling (2011)

    Fulltext@MSK | Save
  • Mutant BRAF melanomas-dependence and resistance
    Journal Article

    Poulikakos, P. I.; Rosen, N.
    Cancer Cell (2011)

    Fulltext@MSK | Save
  • The pan-RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF mutant-selective manner
    Meeting Abstract

    Joseph, E. W.; Pratilas, C. A.; Poulikakos, P. I.; Tadi, M.; Wang, W.; Taylor, B. S.; Persaud, Y.; Xing, F.; Halilovic, E.; Viale, A.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    Journal Article

    Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N.
    Nature (2010)

    Fulltext@MSK | Save
  • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
    Journal Article

    Joseph, E. W.; Pratilas, C. A.; Poulikakos, P. I.; Tadi, M.; Wang, W.; Taylor, B. S.; Halilovic, E.; Persaud, Y.; Xing, F.; Viale, A.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2010)

    Fulltext@MSK | Save
  • Amplification of wild-type BRAF in melanoma is associated with activation of RAF-MEK-ERK signaling and MEK-dependence
    Meeting Abstract

    Blumenthal, E.; Poulikakos, P. I.; Tadi, M.; Grbovic-Huezo, O.; Taylor, B. S.; Janakiraman, M.; Leversha, M.; Viale, A.; Solit, D. B.; Rosen, N.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save